CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: This study examines how chimeric antigen receptor T-cell (CAR-T) therapy’s incremental effectiveness and cost–effectiveness profile fits into the recent history of anticancer treatments. Materials & methods: We conducted graphical and multivariable analyses using data from the Cost–Effectiveness Analysis Registry of the Tufts Medical Center and the Institute for Clinical and Economic Review’s analysis of CAR-T therapies. We collected additional information including the US FDA approval years for pharmacologic innovations. Results: CAR-T provided 5.03 (95% CI: 3.88–6.18) more incremental quality-adjusted life-years than the average pharmaceutical intervention and 4.61 (95% CI: 1.67–7.56) more than the average nonpharmaceutical intervention, while retaining similar cost–effectiveness. There was evidence of worsening cost–effectiveness by approval year for pharmaceutical interventions. Limitations: Analysis is limited to anticancer treatments studied in cost–utility analyses, estimated to cover approximately 60% of FDA-approved antineoplastic agents. Conclusion: CAR-T therapy breaks a pattern of stagnant efficacy growth in pharmaceutical innovation and demonstrates significantly greater incremental effectiveness and similar cost–effectiveness to prior innovations.
Supplementary Material
File (suppl_data.zip)
- Download
- 92.79 KB
References
1.
Harrison CJ. Acute lymphoblastic leukemia. Clin. Lab. Med. 31(4), 631–647 (2011).
2.
Food and Drug Administration. Highlights of prescribing information: Kymriah (2017). www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM573941.pdf
3.
Food and Drug Administration. Highlights of prescribing information: Yescarta (2017). www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM581226.pdf
4.
National Institute for Health and Care Excellence. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (2018). www.nice.org.uk/Guidance/TA554
5.
National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (2019). www.nice.org.uk/Guidance/TA559
6.
European Medicines Agency. Assessment report: Kymriah. p. 186 (2018). www.ema.europa.eu/en/medicines/human/EPAR/kymriah
7.
European Medicines Agency. Yescarta (axicabtagene ciloleucel) summary of opinion (initial authorisation) (2018). www.ema.europa.eu/en/medicines/human/EPAR/yescarta
8.
Novartis leukaemia drug approved in Switzerland (2018). www.swissinfo.ch/eng/sci-tech/kymriah_novartis-leukaemia-drug-approved-in-switzerland/44490894
9.
TGA approves first CAR-T therapy (2018). https://biotechdispatch.com.au/news/tga-approves-first-car-t-therapy
10.
Pharmaceutical Research and Manufacturers of America. Medicines in development for cancer 2018 report (2018). www.phrma.org/en/Report/Medicines-in-Development-for-Cancer-2018-Report
11.
Kaiser Health News. Cascade of costs could push CAR-T therapy to $1.5M per patient (2017). https://endpts.com/cascade-of-costs-could-push-new-gene-therapy-above-1-million-per-patient/
12.
Grady D, FDA. Approves first gene-altering leukemia treatment, costing $475,000. New York Times (2017). www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html
13.
Loftus P, Roland D. FDA approves pioneering cancer treatment with $475,000 price tag (2017). www.wsj.com/articles/fda-approves-first-gene-therapy-in-u-s-1504108512
14.
Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 4(7), 994–996 (2018).
15.
Tice J, Walsh JME, Otuonye I et al. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value. Institute for Clinical and Economic Review Boston, MA (2017).
16.
American Cancer Society. Cancer facts & figures 2018 (2018). www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html
17.
National Cancer Institute. Professional judgment budget proposal (2018). www.cancer.gov/about-nci/budget/plan/budget-proposal-fy-2019
18.
Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J. Econ. Perspect. 29(1), 139–162 (2015).
19.
Mailankody S, Prasad V. Five years of cancer drug approvals: innovation, efficacy, and costs. JAMA Oncol. 1(4), 539–540 (2015).
20.
Soneji S, Yang J. New analysis reexamines the value of cancer care in the United States compared to Western Europe. Health Aff. (Millwood) 34(3), 390–397 (2015).
21.
Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ 359, j4530 (2017).
22.
Saluja R, Arciero VS, Cheng S et al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. J. Oncol. Pract. 14(5), e280–e294 (2018).
23.
Lu Y, Penrod JR, Sood N, Woodby S, Philipson T. Dynamic cost–effectiveness of oncology drugs. Am. J. Manag. Care 18(Suppl. 11), S249–S256 (2012).
24.
Howard DH, Chernew ME, Abdelgawad T, Smith GL, Sollano J, Grabowski DC. New anticancer drugs associated with large increases in costs and life expectancy. Health Aff. (Millwood) 35(9), 1581–1587 (2016).
25.
Stevens W, Philipson TJ, Khan ZM, MacEwan JP, Linthicum MT, Goldman DP. Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995–2007. Health Aff. 34(4), 562–570 (2015).
26.
Center for the Evaluation of Value and Risk in Health. The Cost–Effectiveness Analysis Registry. Tufts Medical Center, MA, USA. https://cevr.tuftsmedicalcenter.org/databases/cea-registry
27.
Greenberg D, Earle C, Fang C-H, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost–utility analyses in oncology. J. Natl Cancer Inst. 102(2), 82–88 (2010).
28.
Neumann PJ, Fang C-H, Cohen JT. 30 Years of pharmaceutical cost–utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics 27(10), 861–872 (2009).
29.
Saret CJ, Winn AN, Shah G et al. Value of innovation in hematologic malignancies: a systematic review of published cost–effectiveness analyses. Blood 125(12), 1866–1869 (2015).
30.
Whittington MD, McQueen RB, Ollendorf DA et al. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 172(12), 1161–1168 (2018).
31.
Tice J, Walsh JME, Otuonye I et al. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Cancers: Effectiveness and Value. Final Evidence Report. Institute for Clinical and Economic Review, MA, USA (2018).
32.
Center for the Evaluation of Value and Risk in Health. The Cost–Effectiveness Analysis (CEA) Registry, User’s Guide (v3.1, 2011–2012). MA, USA (2012).
33.
National Institutes of Health. Genetic and Rare Disease Information Center (2018). https://rarediseases.info.nih.gov/diseases
34.
Garrison LP Jr, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health 12(8), 1118–1123 (2009).
35.
STATA. qreg – Quantile regression (2019). www.stata.com/manuals13/rqreg.pdf
36.
Lin JK, Muffly LS, Spinner MA et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J. Clin. Oncol. 37(24), 2105–2119 (2019).
37.
Roth JA, Sullivan SD, Lin VW et al. Cost–effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J. Med. Econ. 21(12), 1238–1245 (2018).
38.
Lin JK, Lerman BJ, Barnes JI et al. Cost–effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J. Clin. Oncol. 36(32), 3192–3202 (2018).
39.
Whittington MD, McQueen RB, Ollendorf DA et al. Long-term survival and cost–effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-cell lymphoma. JAMA Netw. Open 2(2), e190035 (2019).
40.
Saluja R, Arciero VS, Cheng S et al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. J. Oncol. Pract. 14(5), e280–e294 (2018).
41.
Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost–effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma. J. Clin. Oncol. 36(33), 3307–3314 (2018).
42.
Graham CN, Christodoulopoulou A, Knox HN et al. A within-trial cost–effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. J. Med. Econ. 21(11), 1075–1083 (2018).
43.
Lakdawalla DN, Doshi JA, Garrison LP, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care – a health economics approach: an ISPOR Special Task Force report. Value Health 21(2), 131–139 (2018).
Information & Authors
Information
Published In
Pages: 327 - 340
PubMed: 32056442
Copyright
© 2020 Future Medicine Ltd.
History
Received: 24 May 2019
Accepted: 7 January 2020
Published online: 14 February 2020
Keywords:
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments. (2020) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2019-0065
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Andrea P. Chung, Jason T. Shafrin, Sachin Vadgama, Kristen Hurley, Miguel-Angel Perales, Leonard C. Alsfeld, Sanjana Muthukrishnan, Anik R. Patel, Gunjan L. Shah, Richard T. Maziarz, Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis, Blood Advances, 10.1182/bloodadvances.2024015634, 9, 18, (4727-4735), (2025).
- Qing Xiao, Yi Liu, Tingting Li, Chaoyu Wang, Sanxiu He, Liuyue Zhai, Zailin Yang, Xiaomei Zhang, Yongzhong Wu, Yao Liu, Viral oncogenesis in cancer: from mechanisms to therapeutics, Signal Transduction and Targeted Therapy, 10.1038/s41392-025-02197-9, 10, 1, (2025).
- Elisabete Gonçalves, CAR-T cell therapies: patient access and affordability solutions, Future Science OA, 10.1080/20565623.2025.2483613, 11, 1, (2025).
- Rossana Di Staso, Beatrice Casadei, Marianna Gentilini, Serafina Guadagnuolo, Cinzia Pellegrini, Alessandro Broccoli, Davide Gori, Riccardo Masetti, Vittorio Stefoni, Francesca Bonifazi, Pier Luigi Zinzani, Lisa Argnani, Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity, Annals of Hematology, 10.1007/s00277-024-05766-0, 103, 7, (2499-2509), (2024).
- Mikhail Y. Salnikov, Katelyn M. MacNeil, Joe S. Mymryk, The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape, Frontiers in Immunology, 10.3389/fimmu.2024.1358511, 15, (2024).
- Bijal D. Shah, Nathaniel J. Smith, Chaoling Feng, Sushanth Jeyakumar, Jean-Gabriel Castaigne, Imi Faghmous, Behzad Kharabi Masouleh, Daniel C. Malone, Michael R. Bishop, Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States, Advances in Therapy, 10.1007/s12325-022-02201-6, 39, 8, (3678-3695), (2022).
- Steven Simoens, Katrien De Groote, Cornelis Boersma, Critical Reflections on Reimbursement and Access of Advanced Therapies, Frontiers in Pharmacology, 10.3389/fphar.2022.771966, 13, (2022).
- Meirav Kedmi, Roni Shouval, Shalev Fried, David Bomze, Joshua Fein, Zachary Cohen, Ivetta Danilesko, Noga Shem-Tov, Ronit Yerushalmi, Elad Jacoby, Michal Besser, Avichai Shimoni, Arnon Nagler, Abraham Avigdor, Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma, Transplantation and Cellular Therapy, 10.1016/j.jtct.2022.02.017, 28, 5, (251-257), (2022).
- Hinrich Abken, Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors, Human Gene Therapy, 10.1089/hum.2021.165, 32, 19-20, (1011-1028), (2021).
- Shiho Wakase, Takanori Teshima, Jie Zhang, Qiufei Ma, Yoko Watanabe, Hongbo Yang, Cynthia Z. Qi, Xinglei Chai, Yanwen Xie, Eric Q. Wu, Ataru Igarashi, Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan, Transplantation and Cellular Therapy, 10.1016/j.jtct.2020.12.023, 27, 3, (241.e1-241.e11), (2021).